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Abstract In the literature, several types of microneedles have
been extensively described. However, porous microneedle ar-
rays only receivedminimal attention. Hence, only little is known
about drug delivery via these microneedles. However, porous
microneedle arrays may have potential for future microneedle-
based drug and vaccine delivery and could be a valuable addi-
tion to the other microneedle-based drug delivery approaches.
To gain more insight into porous microneedle technologies, the
scientific and patent literature is reviewed, and we focus on the
possibilities and constraints of porous microneedle technologies
for dermal drug delivery. Furthermore, we show preliminary
data with commercially available porous microneedles and de-
scribe future directions in this field of research.
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Introduction
The skin is an attractive organ for drug and vaccine delivery
because it is easily accessible and has a large surface area that
is available for drug administration, and dermal drug delivery
is potentially pain-free [1–4]. Furthermore, drug delivery via
the skin circumvents the first-pass effect of the liver,
swallowing problems, inconvenient injections, and drug
absorption/stability problems in the gastrointestinal tract [1,
5–7]. Besides, the skin contains a large number of antigen-
presenting cells (i.e., Langerhans cells and dermal dendritic
cells) and is therefore a suitable site for vaccination [8, 9].
However, for transdermal delivery, only about 20 active drug
molecules are on the market, all of them being low-molecular-
weight drugs, illustrating that it is difficult to overcome the
skin barrier [10]. This barrier, i.e., the stratum corneum, com-
plicates foreign compounds, including drugs, from entering
the body. To overcome the stratum corneum barrier, several
drug delivery systems have been developed. One of the most
promising delivery systems are microneedles, which are
needle-like structures with a length of less than 1 mm that
are used to deliver drugs into the skin in a minimally-
invasive and potentially pain free manner [1, 4, 8].
In the literature, two types of microneedles (hollow and
solid) have been extensively described for drug delivery via
four delivery approaches (Fig. 1), as reviewed elsewhere
[11–13] and briefly described below. Drug delivery via hollow
microneedles (a miniaturized form of hypodermic needles) is
achieved by pressing a liquid drug formulation through the
bore of the microneedle into the skin [14–22]. Drug delivery
via solid microneedles is achieved by three technologies. For
drug delivery via microneedle pretreatment, microneedles are
first pierced into the skin and subsequently, a patch with a
drug formulation is applied onto the site of microneedle ap-
plication, leading to diffusion of the drug into the skin
[23–34]. For drug delivery via coated microneedles, the
microneedle surface is first coated with a drug. Upon piercing
of the skin, the drug coating is hydrated and detaches from the
microneedle surface, resulting in delivery of the drug into the
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skin [35–48]. For drug delivery via dissolving microneedles, a
drug is entrapped in microneedles made of a soluble material.
Upon piercing, the microneedles dissolve through hydration,
leading to the delivery of the drug into the skin [49–59]. Each
of these types of delivery approaches has its particular merits
and disadvantages with respect to drug delivery applications
[1]. Another type of microneedles for dermal drug delivery
only received minimal attention in the microneedle field: po-
rous microneedles. Hence, only little is known about drug
delivery via these microneedles. This review focuses on the
possibilities and constraints of porous microneedle technolo-
gies for dermal drug delivery, shows preliminary data with
commercially available porous microneedles, and describes
future directions in this field of research.
Drug delivery via porous microneedle technologies
Dermal drug delivery via porous microneedles differs in sev-
eral aspects from the delivery approaches via solid
microneedles, although there are also similarities. Porous
microneedle arrays are envisaged as a single-unit-drug deliv-
ery system, whereby the whole microneedle array (i.e., the
microneedles and potentially the backplate) contains either a
liquid or a dry drug formulation.
& In case of a liquid formulation: a drug formulation will be
first loaded into the pores of a microneedle array.
Subsequently, the microneedles are pierced into the skin,
and the drug diffuses from the microneedle matrix into the
skin. As the microneedles are depleted of the drug, the
drug diffuses from the drug reservoir (microneedle back-
plate) via the microneedles into the skin. Hence, drug de-
livery via porous microneedles has elements of
microneedle pretreatment (i.e., drug delivery is a
diffusion-based process), with the major technical differ-
ence that porous microneedles remain inside the skin dur-
ing drug delivery.
& In case of a dry formulation: a drug formulation will be
loaded into the pores of the microneedles and dried, e.g.,
by heat, vacuum, or freeze drying. Upon piercing into the
skin, the drug formulation must be hydrated with intersti-
tial fluid (ISF). Hydration can occur via capillary forces of
the pores. Consequently, the dry formulation dissolves and
the drug diffuses from the microneedle pores into the skin,
as described above.
Several patents describe porous microneedles that may po-
tentially be used for drug delivery and/or sampling of biolog-
ical fluids [60–68]. However, so far, only a few research pa-
pers have been published on porous microneedles [69–74].
Among them, one publication reports on the delivery of a
model drug (antibody) into the skin via porous microneedles
[73], and another publication reports on the dermal delivery of
a red hydrophobic dye [74]. Furthermore, porous
microneedles have, to our knowledge, not yet been
Fig. 1 Microneedle-based drug delivery via hollow, solid, and porous microneedles. Image adapted from [1]
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(successfully) applied for dermal immunization, apart from
the very rudimentary results on ovalbumin-antibody re-
sponses in the serum of mice in a small scale animal experi-
ment [75].
In brief, several platform technologies for porous
microneedles exist, utilizing porous silicon [62, 64–66, 68],
colloidal silica [67], polymers [64], and ceramics (e.g., calci-
um phosphate [63], gypsum, brushite [74, 76], and alumina
[60, 72]), as described in detail below. These microneedle
arrays are either completely [60, 62, 64, 66, 72] (i.e., the
microneedles including the backplate) or partially (i.e., only
the microneedle tip) made of a porous material [65, 69]. Al-
ternatively, solid microneedle arrays may be coated with a
porous material [61, 63, 66].
Porous polymeric microneedles
Porous microneedles made of poly lactic acid (PLA), a biode-
gradable polymer, may have several advantages.
Microneedles made of dissolving/biodegradable materials
have the advantage that broken microneedles left inside the
skin will eventually disappear. Thus far, porous PLA
microneedles have been made with a porosity of 75 %. How-
ever, these microneedles lacked strength and were conse-
quently unable to penetrate skin [70]. Therefore, this
microneedle technology requires improvements, e.g., by de-
creasing the porosity to increase the microneedle strength, to
become fit for application in dermal drug delivery in its pres-
ent form.
Porous silicon microneedles
Porous silicon is generally made by electrochemical etching of
plain silicon. Porous silicon is a non-toxic and biocompatible
material that has been produced with a large variety of pore
sizes (1 nm to 10 μm) [77–79] and is, depending on the po-
rosity and pore size, biodegradable into silicic acid [78–80].
Whereas high porosity silicon (>70 % porosity) is completely
biodegradable [78] (e.g., complete dissolution of a 68–70 %
porous silicon (40–60 nm pores) implant occurs within
8 weeks in vivo [79]), low porosity silicon and macroporous
silicon (>50 nm pores) are quite bioinert materials similar to
normal silicon [78]. Silicon is already a brittle material and
making it porous its strength is reduced (e.g., inducing 40 %
porosity into silicon leads to a tenfold decreased mechanical
strength [81]). Hence, porous silicon microneedles may easily
break and stay inside the skin upon piercing. Therefore, po-
rous silicon microneedles should preferably be biodegradable
(thus have a porosity of >70 % and a pore size of <50 nm).
Another disadvantage of porous silicon is that it cannot be
stored under ambient conditions because of the limited stabil-
ity. Degradation (oxidation) naturally occurs over time and
accelerates with increasing moist content, at increasing pH
values, and elevated temperature (thermal oxidation)
[78–80]. Porous microneedles have been produced from sev-
eral types of silicon [35, 82–84]. However, the pore morphol-
ogy (i.e., pore size, orientation, and shape) upon electrochem-
ical etching is dependent on the type of silicon [77–79]. There-
fore, the introduction of pores into silicon microneedles will
not be a general strategy for producing porous microneedles.
Besides, introducing pores lead to a decreased sharpness in
silicon microneedles [69], which could result in a decreased
penetration ability of these microneedles. Finally, the direct
manufacture of microneedles in silicon is relatively expensive
in terms of the starting material as well as the involvedMEMS
processing steps compared to microneedle production tech-
nologies based on microreplication.
In conclusion, porous silicon microneedles may be appli-
cable for drug delivery if produced as high porosity, small
pore-sized silicon. Therefore, this strategy might be limited
to dermal delivery of low-molecular-weight drugs and small
therapeutic peptides.
Microneedles coated with a porous ceramic material
Microneedles with a solid core and a porous shell have been
made by electrochemical coating of solid metal microneedles
(thus having a solid core and porous shell) with calcium phos-
phate, a bioceramic [71]. This has the advantage over
completely porous microneedles that the microneedles (the
core) retain their strength and thereby allow insertion of the
microneedles into the skin [1]. Another advantage of this spe-
cific approach is the large pore size (0.2–0.5 μm), which en-
ables most protein-based and subunit vaccines to be loaded into
the pores of the microneedles. However, the porous calcium
phosphate coating onto microneedles lacks strength, i.e., when
these microneedles are inserted into the skin in the dry state
(i.e., no liquid is loaded in the pores), the calcium phosphate
coating breaks off into or onto the skin [71]. This is especially
undesirable in the skin because calcium phosphate is a second
generation bioceramic (i.e., it is a bioactive material) that pro-
motes cell adhesion [85, 86] and could thereby lead to skin
irritation. Although porous calcium phosphate is a material that
is biodegradable via osteoclastic activity (resorption) and dis-
solution [85–87], it takes a long time before the material is
degraded, e.g., the weight loss of porous calcium in a physio-
logical buffer was about 6 % after 90 days [88].
Dissolving porous ceramic microneedles
Recently, dissolving porous ceramic microneedles have been
made from self-setting ceramics (gypsum (CaS) and brushite
(CaP)) by microreplication techniques. The advantage of this
system is that these self-setting dissolving ceramic
microneedles have an increased mechanical strength as com-
pared to polymeric or sugar-based dissolving microneedles.
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Besides, the pore size and thereby the drug release profile can
be tweaked. These microneedles were used for the delivery of
a red hydrophobic dye in porcine skin by applying dye-coated
self-setting ceramic microneedles onto the skin. Besides,
zolpidem tartrate (307 Da) loaded self-setting ceramic
microneedles released up to 70 % of their content after 48 h
in a cellulose matrix in vitro. However, the drug loading cir-
cumstances for these microneedles are unfavorable for pro-
teins. Drug loading is either performed during the molding
process, requiring 0.5 M citric acid (brushite) or involves an
exothermic reaction (gypsum), or by adding the drug dis-
solved in ethanol post hoc [74, 76]. Therefore, the applicabil-
ity of these microneedles is likely limited to the delivery of
low-molecular-weight drugs.
Porous alumina microneedles
Alumina (Al2O3) is a first generation bioceramic (i.e., this
material has a good chemical stability and is almost bioinert)
[85, 89–91]. Alumina ceramics have good mechanical
strength as compared to monocrystalline silicon (fracture
toughness of 3.75–4.85 MPa·m1/2 [92] and 0.83·–0.94 MPa·
m1/2 [93], respectively). Furthermore, alumina has been used
for implants (e.g., dental implants, bone implants) [89–91,
94]. Porous alumina structures can be made with pores vary-
ing from 10 nm up to hundreds of micrometers [89–91]. As
the microneedle sharpness is an important factor for skin pen-
etration [1] (e.g., microneedles with a tip diameter of <50 nm
may be reproducibly inserted into skin upon manual applica-
tion, whereas microneedles with a tip diameter of 1–5μmmay
require an impact-insertion applicator, to ensure sufficient skin
penetration, depending on the microneedle length and densi-
ty), the alumina particles that are used for producing porous
ceramic microneedles should be sufficiently small to fully fill
the desired mold structure and large enough to produce the
target pore size. Microneedles with a very small pore size will
limit the applicability of the porous alumina microneedle tech-
nology for the delivery of biomacromolecular drugs such as
biologicals and vaccines. Recently, microneedles with an av-
erage pore size of 80 nm have been made from alumina nano-
particles with an average particle diameter of 300 nm [72, 73].
This resulting pore size enables in theory the loading of small
molecules, (therapeutic) peptides, proteins, drugs (e.g., anti-
bodies, cytokines), and (subunit) vaccines, while the
microneedle still retains a sufficient tip sharpness. These
microneedles were successfully used to deliver an antibody
into ex vivo human skin [73], which holds promise for their
use as a macromolecular drug delivery system.
Since the reported data on porous microneedles in dermal
drug delivery are limited to a few studies, we performed in this
work in vitro studies with ceramic (alumina) nanoporous
microneedle arrays (npMNA). These preliminary studies as
described in Characterization of ceramic porous microneedle
arrays in vitro provide guidance for future investigations into
the applicability of porous ceramic microneedles in dermal
drug delivery.




Fluorescein, trypan blue, and fluorescently labeled nanoparti-
cles of 30 nm (carboxylate-modified, fluorescent yellow-
green, λex 470 nm/λem 505 nm), 50 nm (amine-modified,
fluorescent blue, λex 360 nm/λem 420 nm), and 100 nm (sul-
fate-modified, fluorescent orange, λex 520 nm/λem 540 nm)
were purchased from Sigma Aldrich. PBS (pH 7.2) was ob-
tained from Invitrogen, and AKP30 alumina particles were
obtained from Sumitomo Chemical.
Pore volume determination
To determine the pore volume, 24 npMNAs (prepared as pre-
viously described [72]) were first loaded with fluorescein by
totally immersing (dipping) them in a 0.1-mg/mL fluorescein
in PBS (pH 7.2) solution. Subsequently, surface adsorbed liq-
uid was removed by using pressurized nitrogen, and the arrays
were subsequently incubated in 10mL release buffer (PBS) on
a shaking device at 500 rpm. After 1 h, a time point ensuring
100 % release of the fluorescein from the npMNAs, the con-
centration fluorescein in the release buffer was determined,
from which the pore volume was calculated. The concentra-
tion fluorescein was determined by using a calibration curve
(4–250 ng/mL) and measuring the fluorescence on a Syner-
gy™Mx (Bio-Tek) microplate reader in a black 96-well plate
with an excitation wavelength of 494 nm and an emission
wavelength of 521 nm.
Loading and release of a small compound
To determine the release of a low-molecular-weight model
drug from npMNAs, three arrays (with a weight of
±80 mg per array) were loaded with 500 ng fluorescein
by applying a drop of 5 μL 0.1 mg/mL fluorescein in PBS
(pH 7.2) solution onto the microneedles, which was
absorbed within a few seconds. Next, the arrays were
incubated in 10 mL PBS on a shaking device at
500 rpm, and the released fluorescein was determined at
several time points (1–30 min) as described above.
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Loading and release of nanoparticles
To investigate the size limit of molecules that can be loaded
into the npMNAs, the loading and release performance of
fluorescently labeled nanoparticles with a size of 30, 50, and
100 nm was investigated. First, the pore volume (Vpore) of
each of the used npMNAswas determined as described above.
Subsequently, nanoparticles were loaded into the npMNAs by
incubating them in a vial on a shaking device at 500 rpm in a
loading volume (Vloading) of 100 μL, containing 10 mg/mL
(1 % solids) nanoparticles in PBS. As a control a vial with
100 μL of a-10 mg/mL nanoparticle dispersion without a
npMNA was used. After 15 min, the concentration of nano-
particles in the vials with (CMN) and without (Ccontr.) a
npMNA was determined by using a calibration curve and
measuring the specific fluorescence of the fluorescently la-
beled nanoparticles. Subsequently, the amount of loaded
nanoparticles and the loading efficiency (LE, the fraction of
the pore volume that is available for nanoparticle entrapment)
were calculated according to Eqs. 1 and 2, respectively.
Loaded NPs
¼ Vloading  Ccontr:
 
− Vloading− Vpore
   CMN
  ð1Þ
LE ¼ Loaded NPsð Þ= Vpore  Ccontr:
   100% ð2Þ
Next, the extent of liquid was removed from the
microneedle arrays by using pressurized nitrogen, and re-
leased amount of nanoparticles was determined after the ar-
rays were incubated in 10mL release buffer (PBS) for 2 h on a
shaking device at 500 rpm. The release efficiency was defined
as the percentage released nanoparticles of the loaded
nanoparticles.
Microneedles and skin penetration
The penetration ability of npMNAs in ex vivo human skin was
investigated by using empty npMNAs with two different ge-
ometries, as supplied by MyLife Technologies, containing
either 16 microneedles with a length of 370 μm (Fig. 2a) or
126 microneedles with a length of 200 μm per array (Fig. 2b).
The zeta potential of the microneedle material (alumina) was
measured in 0.1×PBS (pH 7.2) on a Zetasizer Nano (Malvern
Instruments). Ex vivo abdomen human skin was obtained
from local hospitals within 24 h after cosmetic surgery and
was dermatomed to a thickness of 600 μm. Subsequently, the
microneedles were placed onto the skin, and the skin was
pierced by applying an impact-insertion applicator onto the
microneedles with a velocity of 3 m/s [95]. This procedure
was repeated five times with both microneedle arrays. Next, a
drop of 70 μLTrypan blue was applied for 1 h, after which the
skin was washed once with 70 % ethanol and twice with PBS.
Finally, the stratum corneum was removed by tape-stripping
(Scotch tape) as previously described [34].
Results and discussion
Pore volume
The pore volume is an important factor for the amount of
drugs that can be loaded into porous microneedle arrays.
Therefore, the pore volume of npMNAs with varying weights
was determined, as shown in Fig. 3a. Besides, Fig. 3b shows
that npMNAs have a reproducible pore volume (10.52±
0.88 μL/100 mg microneedle array, mean±SD, n=24). This
implies that these microneedle arrays, having an average den-
sity of 3.84 g/cm3, have a porosity of 40.41±3.40 % (mean±
SD, n=24), which is comparable to reported values [73].
Release of a small molecule
npMNAs (±80 mg/array) loaded with 5 μL of a 0.1-mg/
mL fluorescein solution efficiently released their contents
within 30 min upon incubation in 10 mL PBS (Fig. 3c),
which represents a fast release for low-molecular-weight
drugs in vitro. However, in case of a dermal application,
the surface of the microneedles that is inside the skin
determines how fast small molecules diffuse from the
microneedle arrays into the skin, because molecules can
only diffuse from the microneedle surface that is pierced
into the skin. There are several product-related factors
that determine the rate of drug delivery, e.g., the solubil-
ity and concentration of the drug molecule, the thickness
of the backplate, and the properties of the microneedle
array itself (e.g., length, sharpness, porosity, strength,
surface area, density [34, 35, 70]). However, the rate of
drug delivery is also dependent on variables more diffi-
cult to control: the quality of the penetration (i.e., the
depth of microneedle insertion and the penetration effi-
ciency), the manner of microneedle application (e.g., ap-
plied force, time of application, usage of an applicator
[34, 96]), and on the type of skin (e.g., elasticity and
subcutaneous fat/dermis/stratum corneum thickness that
varies by age, gender, race, illness, genetic factors, body
weight, etc. [97–100]). To gain more insight into the
usability of the npMNAs for drug release into the skin,
diffusion studies should be performed.
Loading and release of nanoparticles
In order to have a size range in which proteins and vaccines
can be loaded into npMNAs, fluorescently labeled nanoparti-
cles with different sizes were used. As represented in Fig. 4a,
this led to a loading of 94, 58, and 16 μg for 30, 50, and
100 nm nanoparticles, respectively, showing that the total
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amount of nanoparticles that was loaded into the npMNAs
(±80 mg/array) was dependent on the nanoparticle size. As
shown in Fig. 4b, 30 nm nanoparticles (88 %) and 50 nm
nanoparticles (54 %) were efficiently loaded into the
npMNAs. Besides, even nanoparticles of 100 nmwere loaded
into the npMNAs albeit with a substantially lower loading
efficiency of 15%. Next, the amount of released nanoparticles
from nanoparticle-loaded npMNAs was determined, showing
that 27 (29 %), 2 (4 %), and 1 μg (6 %) of the 30, 50, and
100 nm nanoparticles were released, respectively (Fig. 4c, d).
However, the release of the 50 nm nanoparticles was relatively
low, which could be due to adsorption of the nanoparticles to
the microneedle inner surface, which is likely a result of the
nanoparticle charge, i.e., the 30 nm and 100 nm are negatively
charged, and the 50 nm nanoparticles are positively charged,
whereas alumina is negatively charged (zeta potential of
−18 mVat pH 7.2).
In conclusion, these data show that particles with a
size up to 100 nm can be loaded into the npMNAs,
although not very efficiently for the 100 nm nanoparti-
cles. Both the loading and the release efficiency are
dependent on the particle size and likely on the surface
charges. Nevertheless, the experiments with these model
compounds indicate that a large variety of drugs, in-
cluding proteins and vaccines can be potentially loaded
and released from the npMNAs. To gain more insight
into the usability of the npMNAs for drug delivery,
loading of biomacromolecules and vaccines with differ-
en t s izes , geomet r ies , and charges should be
investigated.
Fig. 2 Nanoporous ceramic
microneedle arrays (MyLife
Technologies) containing 16
microneedles with a length of
370 μm (a) and 126 microneedles
with a length of 200 μm (b)














































































Fig. 3 Pore volume as a function
of weight of 24 individual
microneedle arrays (a) and the
normalized pore volume (b).
Release of fluorescein (mean±
SD, n=3) from 500 ng fluorescein
loaded nanoporous microneedle
arrays in PBS with a weight of
±80 mg/array (c)
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Skin penetration
The penetration of skin is essential to enable dermal drug
delivery through the use of (porous) microneedles. The
efficiency and reproducibility of microneedle insertion
affects the rate of drug delivery, e.g., more and deeper
penetrations will lead to a faster diffusion/delivery of the
drug. Therefore, the penetration ability of npMNAs was
investigated (Fig. 5). As shown in Fig. 5a, it was ob-
served that empty npMNAs, containing 16 microneedles
with a length of 370 μm, which were applied six times,
were efficiently (100 %) and reproducibly inserted into
ex vivo human skin. Besides, no visible breakage of the
microneedles was observed, as also observed by all
microneedles penetrating the skin after the sixth applica-
tion. The npMNAs containing 126 microneedles with a
length of 200 μm also efficiently and reproducibly (84.5
±3.6 %; mean±SD, n=6) penetrated ex vivo human skin
(Fig. 5b). Also for these npMNAs, no visible breakage of
the microneedles was observed after six applications.
From the first to the sixth application, 108, 103, 101,










































































































































































arrays (npMNAs). The amount of
loaded nanoparticles into
npMNAs (a), and the loading
efficiency (b). The amount of
released nanoparticles after 2 h in
PBS at room temperature from
nanoparticle-loaded npMNAs (c),
and the released nanoparticles
expressed in percentage (d).
Results are represented as mean±
SD, n=3
Fig. 5 Six subsequent penetrations of ex vivo human skin by a ceramic nanoporous microneedle array (1–6 respectively), that contained 16
microneedles with a length of 370 μm (a) or 126 microneedles with a length of 200 μm (b). The size bar represents 1 mm
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were counted, respectively, showing that these npMNAs
can efficiently and reproducibly penetrate human skin.
Future directions and perspectives
In this study, ceramic npMNAs have shown to be efficiently
and reproducibly loadedwith small molecules as well as nano-
particles. Moreover, results show the release of a small mole-
cule and nanoparticles up to 100 nm in vitro. Furthermore, we
have shown that npMNAs are able to efficiently and repro-
ducibly pierce ex vivo human skin. Besides, we did not ob-
serve breakage of the microneedles. Although alumina is a
biocompatible and bioinert material, it is not biodegradable.
Therefore, the next step is to investigate how skin reacts when
ceramic npMNAs are applied in vivo. It is also envisaged to
implement ceramic npMNAs with an application device that
facilitates efficient and reproducible microneedle insertion.
Currently, various therapeutic model compounds are tested
in combination with the ceramic npMNAs using a human skin
explant model. Furthermore, several antigens with different
sizes (e.g., tetanus, diphtheria, hepatitis B, polio, and influen-
za) are currently under investigation for their loading ability
into the ceramic npMNAs and the subsequent release in vitro
and into ex vivo human skin. Future studies shall elucidate
more details of the pharmacodynamics as well as the pharma-
cokinetic response upon utilizing porous microneedles for
drug and vaccine delivery. In conclusion, npMNAs may have
potential for future microneedle-based drug and vaccine de-
livery and could be a valuable addition to the other
microneedle-based drug delivery approaches.
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